Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT02367352 Terminated - Ovarian Cancer Clinical Trials

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

Start date: March 19, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability and determine the MTD to subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian participants with advanced solid tumors.

NCT ID: NCT02354898 Completed - Clinical trials for Hepatocellular Carcinoma

A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma

Start date: March 2015
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, phase 1 dose escalation study of BBI503 monotherapy, or BBI503 in combination with Sorafenib. This study population is adult patients with advanced solid tumors in monotherapy, or adult patients with advanced hepatocellular carcinoma in combination therapy.

NCT ID: NCT02318394 Completed - Clinical trials for Advanced Solid Tumors

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

Start date: March 2, 2015
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of MEDI0562 in adult subjects with selected advanced solid tumors

NCT ID: NCT02318329 Completed - Gastric Cancer Clinical Trials

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Start date: November 2014
Phase: Phase 1
Study type: Interventional

This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.

NCT ID: NCT02316197 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Start date: December 31, 2014
Phase: Phase 1
Study type: Interventional

MSC2490484A is an investigational drug that is being evaluated for the treatment of subjects with advanced solid tumors or chronic lymphocytic leukemia (CLL) that likely differs from other cancers in how it repairs damaged DNA (genetic material). This is a first-in-man Phase I study, which means that it is the first time the study drug is being used in humans. The main purpose is to determine the highest dose that does not cause unacceptable side effects. The second is to determine the appropriate dose to use in future research for subjects with cancer. Othergoals of the study are to learn about the drug's safety and side effects, how it affects the tumor, and how the body processes the drug.

NCT ID: NCT02301130 Completed - Clinical trials for Advanced Solid Tumors

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Start date: November 26, 2014
Phase: Phase 1
Study type: Interventional

Mogamulizumab in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors

NCT ID: NCT02301117 Completed - Clinical trials for Advanced Solid Tumors

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Start date: January 2015
Phase: Phase 1
Study type: Interventional

Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.

NCT ID: NCT02301104 Completed - Clinical trials for Advanced Solid Tumors

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

Start date: January 2015
Phase: Phase 1
Study type: Interventional

Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of hepatic impairment.

NCT ID: NCT02281409 Completed - Clinical trials for Advanced Solid Tumors

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Start date: October 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out what effects, good and/or bad, KW-0761, an investigational drug, has on the patient and their cancer.

NCT ID: NCT02266745 Active, not recruiting - Clinical trials for Advanced Solid Tumors

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Start date: July 2014
Phase: Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase and the Dose Expansion Phase. The Dose Escalation Phase will determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 dose(s) (RP2D) of PT-112 Injection and evaluate its safety and tolerability, and PK (pharmacokinetics). The Dose Escalation Phase is complete and no longer enrolling. The Dose Expansion Phase has two cohorts: one cohort for the study of PT-112 in patients with thymoma and thymic carcinoma (Cohort A), and one cohort for the study of PT-112 in metastatic castrate-resistant prostate cancer (mCRPC) (Cohort D).